Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung Biologics, Dinona Partner on Potential COVID-19 Antibody Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Samsung Biologics, Dinona Partner on Potential COVID-19 Antibody Therapy

Will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Biologics has entered into an agreement with biotech Dinona, further expanding its capabilities to provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing. The companies will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

Samsung’s contract development business has been growing with close to 60 contracts signed in just two years. The business segment continues to expand its market reach through various biologics products beyond monoclonal antibodies and by targeting diverse treatment areas including cancer, neurodegenerative diseases, and as with this partnership, COVID-19 treatment.

Samsung Biologics has also recently introduced its cell-line technology, S-CHOice, this year showing improved titers up to two-fold from the industry average and maintaining over 90% cell viability. With a customized development strategy, the company has dramatically reduced the time required for the development stage, taking six months to clinical material manufacturing and seven months to DP release, according to the company.

“Samsung Biologics is always committed to providing the highest quality services to our clients globally to help biotech companies like Dinona focus on their core business, which is drug discovery,” said Tae Han Kim, CEO Samsung Biologics. “As with all our partnerships, we will closely collaborate with our client Dinona to provide the highest client satisfaction and support in its endeavor to bring a potential COVID-19 treatment to market faster and better.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics